Elm3 Financial Group LLC Sells 1,016 Shares of Eli Lilly and Company $LLY

Elm3 Financial Group LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 17.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,898 shares of the company’s stock after selling 1,016 shares during the quarter. Eli Lilly and Company accounts for 3.1% of Elm3 Financial Group LLC’s investment portfolio, making the stock its 8th largest holding. Elm3 Financial Group LLC’s holdings in Eli Lilly and Company were worth $3,737,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC lifted its position in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Eli Lilly and Company by 499.5% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 18,088 shares of the company’s stock valued at $14,939,000 after buying an additional 15,071 shares during the period. Petrus Trust Company LTA acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $425,000. Finally, Raab & Moskowitz Asset Management LLC grew its holdings in Eli Lilly and Company by 3.1% during the first quarter. Raab & Moskowitz Asset Management LLC now owns 1,996 shares of the company’s stock worth $1,649,000 after acquiring an additional 60 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,079.83 on Monday. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The company has a market capitalization of $1.02 trillion, a P/E ratio of 52.83, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. The firm has a 50-day moving average price of $1,013.16 and a two-hundred day moving average price of $851.29. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 33.86%.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Guggenheim reiterated a “buy” rating and issued a $1,163.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Finally, Bank of America reduced their price target on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. Five equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $1,155.36.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.